Interim Safety Analysis or Re-Screening [Design Issues]

posted by professionalr – India, 2025-01-09 23:56 (34 d 01:37 ago) – Posting: # 24336
Views: 556

Hi all,

We are planning to conduct a bioequivalence study for submission in Egypt. The molecules of interest necessitate a washout period of approximately three months in a crossover design. Should we perform re-screening/interim safety analysis before the dosing of Period II?


Edit: Category changed; see also this post #1[Helmut]

Thanks,
RP.

Complete thread:

UA Flag
Activity
 Admin contact
23,380 posts in 4,914 threads, 1,661 registered users;
31 visitors (0 registered, 31 guests [including 4 identified bots]).
Forum time: 01:34 CET (Europe/Vienna)

Everything is trivial, if you know the answer.    Thomas Jaki

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5